Mode
Text Size
Log in / Sign up
Phase 3 N=310 Randomized Double-blind Basic Science

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

Allergic Conjunctivitis

Enrolled (actual)
310
Serious AEs
0.7%
Results posted
Nov 2010
Primary outcome: Primary: Lid and Lid Margin Erythema, Change From Baseline — 0; 0 Units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
K-Lens (generic name not established) and Ketotifen (Device); Placebo Lens (Device)
Age
Pediatric, Adult, Older Adult · 8+ yrs
Sex
All
Sponsor
Vistakon Pharmaceuticals
Primary completion
Feb 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Lid and Lid Margin Erythema, Change From Baseline
0; 0
PRIMARY
Lid and Lid Margin Swelling, Change From Baseline
0; 0
PRIMARY
Conjunctival Redness, Change From Baseline
0; -0.1
PRIMARY
Conjunctival Chemosis, Change From Baseline
0; 0
PRIMARY
Corneal Edema, Change From Baseline
0; 0
PRIMARY
Corneal Erosion, Change From Baseline
0; 0
PRIMARY
Corneal Endothelial, Change From Baseline
0; 0
PRIMARY
Lens Pathology, Change From Baseline
0; -0.1
PRIMARY
Flare in Anterior Chamber, Change From Baseline
0; 0
PRIMARY
Cells in Anterior Chamber, Change From Baseline
0; 0
PRIMARY
Corneal Staining - Nasal, Change From Baseline
-0.1; 0
PRIMARY
Corneal Staining - Temporal, Change From Baseline
0; 0
PRIMARY
Corneal Staining - Inferior, Change From Baseline
0; 0
PRIMARY
Corneal Staining - Superior, Change From Baseline
0; 0
PRIMARY
Corneal Staining - Central, Change From Baseline
0; 0
PRIMARY
Intraocular Pressure, Change From Baseline
-0.3; -0.4
PRIMARY
Dilated Ophthalmoscopy - Fundus, Change From Baseline
-0.1; 0
PRIMARY
Dilated Ophthalmoscopy - Vitreous, Change From Baseline
0; 0
PRIMARY
Visual Acuity Assessment
362; 178

Summary

The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers

Eligibility Criteria

Inclusion Criteria

  • healthy normal, soft contact lens wearing volunteers
  • normal ocular health
  • contact lens correction from +6.00 to -12.00D in each eye and astigmatism of -1.00D or less in each eye

Exclusion Criteria

  • active ocular infection
  • history of ocular surgery
  • use of topical ophthalmic preparations (including rewetting drops)
  • pregnancy or lactation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00569777). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search